Özet:

The aim of the work is to analyze and systematize literature data on the benefits of clinical and economic efficiency, safety of cetuximab in the treatment of colorectal cancer. Materials and methods. Studies were conducted using databases on the Internet: PubMed; Food and Drug Administration, European Medicines Agency. It has used retrospective, logical, statistical and system-analytical research methods. Results. The analysis of clinical data suggests additional utility, high efficacy of cetuximab in the treatment of patients with metastatic colorectal cancer RAS wild type and expression of epidermal growth factor receptors EGFR compared to other drugs. Cetuximab exhibits a synergistic effect with a number of cytostatic drugs, and also increases the effect of radiotherapy, with no increased toxic reactions when co-administered. The administration of cetuximab in the treatment regimen increases the resectability of primary nonresectable metastases in the liver, as well as survival without progression in both operated patients and in inoperable cases. The drug is considered relatively safe. Skin rashes caused by cetuximab are associated with a significant improvement in overall survival, progression-free survival and overall response rates. The use of cetuximab in patients with colorectal cancer is accompanied by a lower economic burden on the budget of drug provision for cancer patients than bevacizumab. It should be noted that the development of cetuximab biosimilars will reduce the cost of treatment and improve access to colorectal cancer therapy. Conclusions. Thus, it has been shown that cetuximab is not only a clinically effective and relatively safe drug for the treatment of colorectal cancer, but also demonstrates its cost-effectiveness and additional benefits compared with other drugs, including bevacizumab Author Biography Elena Litvinova, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002 Doctor of Pharmaceutical Sciences, Associate Professor Department of Management and Economics of Enterprise

Anahtar Kelimeler: